Citi lowered the firm’s price target on ArriVent Biopharma (AVBP) to $31 from $33 and keeps a Buy rating on the shares.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AVBP:
- ArriVent BioPharma Reports Q3 2025 Financial Results
- ArriVent BioPharma’s Promising Trial Results and Strategic Developments Drive Buy Rating
- ArriVent Biopharma reports Q3 EPS (83c), consensus (78c)
- ArriVent Biopharma price target raised to $47 from $32 at Clear Street
- ArriVent BioPharma’s Phase 3 Study on Firmonertinib: A Potential Game-Changer in NSCLC Treatment